vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and Token Cat Ltd (TC). Click either name above to swap in a different company.
Citius Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($3.9M vs $2.8M, roughly 1.4× Token Cat Ltd). Token Cat Ltd runs the higher net margin — -3.4% vs -238.2%, a 234.8% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
CTXR vs TC — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $2.8M |
| Net Profit | $-9.4M | $-93.0K |
| Gross Margin | 80.0% | 79.0% |
| Operating Margin | -228.7% | -206.9% |
| Net Margin | -238.2% | -3.4% |
| Revenue YoY | — | -37.9% |
| Net Profit YoY | 8.6% | 98.3% |
| EPS (diluted) | $-0.38 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | — | ||
| Q2 25 | — | $2.8M | ||
| Q2 24 | — | $4.4M | ||
| Q2 23 | — | $12.7M | ||
| Q2 22 | — | $13.3M |
| Q4 25 | $-9.4M | — | ||
| Q2 25 | — | $-93.0K | ||
| Q2 24 | — | $-5.6M | ||
| Q2 23 | — | $-4.2M | ||
| Q2 22 | — | $-8.4M |
| Q4 25 | 80.0% | — | ||
| Q2 25 | — | 79.0% | ||
| Q2 24 | — | 69.2% | ||
| Q2 23 | — | 63.4% | ||
| Q2 22 | — | 81.0% |
| Q4 25 | -228.7% | — | ||
| Q2 25 | — | -206.9% | ||
| Q2 24 | — | -146.9% | ||
| Q2 23 | — | -59.9% | ||
| Q2 22 | — | -49.6% |
| Q4 25 | -238.2% | — | ||
| Q2 25 | — | -3.4% | ||
| Q2 24 | — | -125.9% | ||
| Q2 23 | — | -33.3% | ||
| Q2 22 | — | -62.9% |
| Q4 25 | $-0.38 | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $150.0K |
| Total DebtLower is stronger | — | $1.4M |
| Stockholders' EquityBook value | $80.0M | $4.6M |
| Total Assets | $140.4M | $28.4M |
| Debt / EquityLower = less leverage | — | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | — | ||
| Q2 25 | — | $150.0K | ||
| Q2 24 | — | $689.0K | ||
| Q2 23 | — | $3.0M | ||
| Q2 22 | — | $4.8M |
| Q4 25 | — | — | ||
| Q2 25 | — | $1.4M | ||
| Q2 24 | — | $1.8M | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q4 25 | $80.0M | — | ||
| Q2 25 | — | $4.6M | ||
| Q2 24 | — | $-787.0K | ||
| Q2 23 | — | $9.1M | ||
| Q2 22 | — | $21.4M |
| Q4 25 | $140.4M | — | ||
| Q2 25 | — | $28.4M | ||
| Q2 24 | — | $12.5M | ||
| Q2 23 | — | $25.1M | ||
| Q2 22 | — | $40.6M |
| Q4 25 | — | — | ||
| Q2 25 | — | 0.30× | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $-23.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | — | ||
| Q2 25 | — | $-23.7M | ||
| Q2 24 | — | $-1.5M | ||
| Q2 23 | — | $-7.2M | ||
| Q2 22 | — | $-8.3M |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | $-1.5M | ||
| Q2 23 | — | — | ||
| Q2 22 | — | $-8.3M |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | -34.4% | ||
| Q2 23 | — | — | ||
| Q2 22 | — | -62.2% |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | 0.0% | ||
| Q2 23 | — | — | ||
| Q2 22 | — | 0.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
